1. Home
  2. VNRX vs DBVT Comparison

VNRX vs DBVT Comparison

Compare VNRX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNRX
  • DBVT
  • Stock Information
  • Founded
  • VNRX N/A
  • DBVT 2002
  • Country
  • VNRX United States
  • DBVT France
  • Employees
  • VNRX N/A
  • DBVT N/A
  • Industry
  • VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VNRX Health Care
  • DBVT Health Care
  • Exchange
  • VNRX Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • VNRX 67.2M
  • DBVT 67.8M
  • IPO Year
  • VNRX N/A
  • DBVT N/A
  • Fundamental
  • Price
  • VNRX $0.68
  • DBVT $0.59
  • Analyst Decision
  • VNRX Strong Buy
  • DBVT Strong Buy
  • Analyst Count
  • VNRX 4
  • DBVT 2
  • Target Price
  • VNRX $4.17
  • DBVT $6.00
  • AVG Volume (30 Days)
  • VNRX 135.1K
  • DBVT 2.0M
  • Earning Date
  • VNRX 11-14-2024
  • DBVT 11-06-2024
  • Dividend Yield
  • VNRX N/A
  • DBVT N/A
  • EPS Growth
  • VNRX N/A
  • DBVT N/A
  • EPS
  • VNRX N/A
  • DBVT N/A
  • Revenue
  • VNRX $1,285,827.00
  • DBVT $12,515,000.00
  • Revenue This Year
  • VNRX $180.66
  • DBVT N/A
  • Revenue Next Year
  • VNRX $558.69
  • DBVT $2,860.00
  • P/E Ratio
  • VNRX N/A
  • DBVT N/A
  • Revenue Growth
  • VNRX 88.32
  • DBVT 125.54
  • 52 Week Low
  • VNRX $0.43
  • DBVT $0.50
  • 52 Week High
  • VNRX $1.23
  • DBVT $2.14
  • Technical
  • Relative Strength Index (RSI)
  • VNRX 50.19
  • DBVT 34.55
  • Support Level
  • VNRX $0.55
  • DBVT $0.56
  • Resistance Level
  • VNRX $0.80
  • DBVT $0.81
  • Average True Range (ATR)
  • VNRX 0.07
  • DBVT 0.05
  • MACD
  • VNRX 0.01
  • DBVT -0.02
  • Stochastic Oscillator
  • VNRX 52.00
  • DBVT 10.42

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: